A PHASE 2, OPEN-LABEL STUDY TO PROVIDE REVISION OF SCARS RESULTING FROM SURGERY IN PRIOR STUDIES OF EXC 001
Latest Information Update: 17 Aug 2021
At a glance
- Drugs PF 6473871 (Primary)
- Indications Scars
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 09 May 2014 New trial record